ARDX
Ardelyx Inc
NASDAQ · Biotechnology
$7.32
+0.32 (+4.57%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 344.59M | 628.50M | 556.78M | 692.55M |
| Net Income | -40,430,926 | -29,854,842 | -22,621,785 | -27,854,629 |
| EPS | — | — | — | — |
| Profit Margin | -11.7% | -4.8% | -4.1% | -4.0% |
| Rev Growth | +220.9% | +14.6% | +16.2% | +24.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 413.86M | 284.78M | 237.65M | 275.35M |
| Total Equity | 475.43M | 688.56M | 638.29M | 606.79M |
| D/E Ratio | 0.87 | 0.41 | 0.37 | 0.45 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -24,589,000 | -37,891,031 | -31,484,723 | -42,657,512 |
| Free Cash Flow | — | -23,199,305 | -21,445,059 | -24,067,993 |